The move marks Italy’s Angelini Pharma’s entry into the U.S. market.
Angelini Pharma’s $4.1B buyout of Catalyst (CPRX) at $31.50/share offers a 28% premium and Q3 2026 close outlook—read the deal details now.
Electroreduction offers a promising route for converting CO2 into value-added chemicals using renewable electricity. Among the possible products, formic acid is particularly attractive because it is ...
In a recent article, researchers from the University of Jyväskylä, Finland, emphasize the importance of multiscale modeling of catalysis in understanding and developing (electro)chemical processes.
As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 ...
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) to Angelini Pharma S.p.A. for $31.50 per share in cash.
A visualization of the exterior of the Catalyst building when completed from a bird’s-eye view. Renderings courtesy of Koelbel and Company. A new healthcare innovation hub opening in Omaha in early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results